Duffy Null Treatment Dosing for Cancer Patients
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Recruiting
Phase 1
Interventional Study
Multiple Myeloma
Triple Negative Breast Cancer
Duffy Blood Group, Chemokine Receptor Gene Mutation
Duffy Blood Group, Chemokine Receptor Gene C.-67T>C
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 90 (estimated)
- Sponsor
- Andrew Hantel, MD · Other
Who this trial is looking for
This trial is looking for people with a specific genetic trait called Duffy null who are being treated for multiple myeloma or triple negative breast cancer. Participants will receive certain cancer medications while the study monitors their treatment and any side effects.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with multiple myeloma or triple negative breast cancer.
- I am currently receiving treatment or planning to start treatment.
- I have a confirmed Duffy null phenotype.
- I am 18 years old or older.
You may not be able to join if
- I cannot understand and sign a consent form.
- My neutrophil count is below 500.
- I have already started my second cycle of treatment.
- I have received specific other medications before joining this trial.
- I am taking any other investigational drugs.
- I have another condition or medication affecting my neutrophils.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose modifications and avoid neutropenic fever (fever in the setting of low neutrophils) for people with Duffy null phenotype receiving treatment for multiple myeloma or triple negative br…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of:
* Cohort 1: MM, based on IMWG criteria12, and currently requires treatment
* Cohort 2: Stage II or III TNBC, with definition per protocol Section 3.2.1 AND
* Plan for treatment, per their treating physician, or currently receiving their first cycle (see 3.3.…
Contacts